Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vitiligo Clear all
Completed Phase 2 Interventional Results available

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

NCT03715829
View directory record Official record
Conditions
Active Non-segmental Vitiligo
Interventions
PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
40
States / cities
Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Not applicable Interventional

A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo

NCT05053022
View directory record Official record
Conditions
Vitiligo
Interventions
Skinpen Precision System
Device
Lead sponsor
Crown Laboratories, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 21, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

NCT07108283
View directory record Official record
Conditions
Nonsegmental Vitiligo
Interventions
Zasocitinib, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Bryant, Arkansas • Fountain Valley, California • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 2:27 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

NCT06109649
View directory record Official record
Conditions
Vitiligo
Interventions
Afamelanotide and NB-UVB Light, NB-UVB Light
Drug · Procedure
Lead sponsor
Clinuvel, Inc.
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
25
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

NCT05971381
View directory record Official record
Conditions
Vitiligo
Interventions
RECELL® Autologous Cell Harvesting Device
Device
Lead sponsor
Avita Medical
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Scottsdale, Arizona • Irvine, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 21, 2026, 2:27 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Examination Of Vitiligo Skin Samples Before and After UVB Treatment

NCT00177034
View directory record Official record
Conditions
Vitiligo
Interventions
Narrow Band UVB Treatment
Drug
Lead sponsor
Mimi Cho, MD
Individual
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Jul 21, 2026, 2:27 PM EDT
Withdrawn Phase 2 Interventional

Evaluating the Efficacy and Safety of Metformin in Vitiligo

NCT05607316
View directory record Official record
Conditions
Vitiligo
Interventions
Metformin Hydrochloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of Etanercept in Adults With Vitiligo

NCT00134368
View directory record Official record
Conditions
Vitiligo
Interventions
Etanercept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Photocil (Topical) for the Treatment of Vitiligo

NCT01992185
View directory record Official record
Conditions
Vitiligo
Interventions
Photocil for Vitiligo, Placebo - Sunscreen (SPF 2)
Drug · Other
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Jul 21, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional Results available

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

NCT06113328
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
MK-6194, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress Response Pathways in Vitiligo

NCT02797574
View directory record Official record
Conditions
Vitiligo
Interventions
Punch Biopsy at a Lesional Site, Punch Biopsy at a Non- Lesional site
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 21, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

NCT07105254
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
Roflumilast topical 0.3% foam
Drug
Lead sponsor
Derm Texas, PLLC
Network
Eligibility
2 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Jul 21, 2026, 2:27 PM EDT
Withdrawn Not applicable Interventional

Hair Transplantation for Treatment of Vitiligo

NCT04858152
View directory record Official record
Conditions
Vitiligo
Interventions
Follicular Unit Extraction via punch biopsy
Procedure
Lead sponsor
Mehdi Rashighi
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Jul 21, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo

NCT01401374
View directory record Official record
Conditions
Vitiligo Vulgaris
Interventions
Not listed
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
Not listed
Enrollment
3,258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

NCT04896385
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 21, 2026, 2:27 PM EDT
Not listed Phase 2 Interventional

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

NCT05210582
View directory record Official record
Conditions
Vitiligo
Interventions
Afamelanotide
Drug
Lead sponsor
Clinuvel, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 21, 2026, 2:27 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Hoover, Alabama • Irvine, California • Santa Monica, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03123016
View directory record Official record
Conditions
Vitiligo
Interventions
Apremilast, NB-UVB phototherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 21, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional Results available

A New Micrografting Technique for Vitiligo

NCT01262547
View directory record Official record
Conditions
Vitiligo
Interventions
Dermabrasion-Micrografting, Dermabrasion
Device · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib for the Treatment of Vitiligo

NCT02809976
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib 1.5% Phosphate Cream
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo

NCT00367224
View directory record Official record
Conditions
Vitiligo
Interventions
6 to 9 ultraviolet B treatments, Skin biopsies
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 21, 2026, 2:27 PM EDT
Active, not recruiting Phase 3 Interventional

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326
View directory record Official record
Conditions
Vitiligo
Interventions
Ritlecitinib, Ritlecitinib 100 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

NCT05750823
View directory record Official record
Conditions
Nonsegmental Vitiligo With Genital Involvement
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Fremont, California • Los Angeles, California • Fort Gratiot, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 2:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

NCT04818346
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Hoover, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 21, 2026, 2:27 PM EDT